• Explore /
  • Poster
  • / A first-in-human phase 1 trial of T cell membrane-anchored tumor targeted IL12 (ATTIL12) -T cell therapy in advanced/metastatic soft tissue and bone sarcoma.

A first-in-human phase 1 trial of T cell membrane-anchored tumor targeted IL12 (ATTIL12) -T cell therapy in advanced/metastatic soft tissue and bone sarcoma.

Abstract Poster

Authors

J. Livingston

J. Andrew Livingston

Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

J. Andrew Livingston , Dristhi Ragoonanan , Priti Tewari , Jonathan Benjamin Gill , Sofia Banck , Meng Gao , Heather Y. Lin , Yisheng Li , Xueqing Xia , Jiemiao Hu , Yining Jin , Elizabeth J. Shpall , Indreshpal Kaur , Tigist Asfaw , F. Enrique Alvarez , Wei-Lien Wang , Neeta Somaiah , Shreyaskumar Patel , Richard Greg Gorlick , Shulin Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Bone Tumors

Clinical Trial Registration Number

NCT05621668

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS11586)

DOI

10.1200/JCO.2024.42.16_suppl.TPS11586

Abstract #

TPS11586

Poster Bd #

512a

Abstract Disclosures

Similar Posters

First Author: Meredith McKean

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.

Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.

First Author: C. Marcela Diaz-Montero

First Author: Rongsu Qi

First Author: Michael Bitzer